{
    "title": "Proteomic profile of follicular fluid from patients with polycystic\novary syndrome (PCOS) submitted to",
    "journal": "JBRA Assisted Reproduction",
    "publication_date": "2019",
    "abstract": "The follicular fluid (FF) of women with polycystic ovary syndrome (PCOS)\nseems to exhibit a profile different from that of fertile women, which may\nbe related to folliculogenesis disruption in PCOS patients. The aim of this\nstudy was to evaluate the differentially expressed proteins in the FF of\nwomen with PCOS compared to oocyte donors (ODs). This screening study included thirteen (13) women who underwent  The FF of the patients was matched to 229 proteins, with 61 proteins\nexclusive to the PCOS group, 123 proteins exclusive to the ODs, and 45\nproteins found in both groups. We highlight fetuin-A and vitamin D ligand\nprotein, which were exclusively expressed in the PCOS group; Complement C3\noverexpressed in the PCOS group; and 26S protease only expressed in the OD\ngroup. The canonical pathways LXR/RXR activation, FXR/RXR activation,\nprothrombin activation are directly related to the disrupted metabolism and\nincreased inflammatory status found in PCOS patients. The findings of the differentially expressed proteins and matched pathways\nare associated with folliculogenesis, indicating it relevance to oocyte\nquality.",
    "body": "INTRODUCTION  Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, ovulation\ndisorder and polycystic ovaries (PCO) and the exclusion of other endocrinopaties\n( Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus\nWorkshop Group, 2004 ). PCOS affects 6-8% of women of reproductive age.\nAlthough PCOS was first described eighty years ago ( Stein & Leventhal, 1935 ), its aetiology is not yet fully elucidated,\nas it is a heterogeneous and complex disorder with metabolic and reproductive\nimplications. PCOS represents the major ovulatory cause of infertility, which leads\nsome PCOS patients to pursue in vitro fertilization (IVF)\ntreatments ( Dumesic et al .,\n2015 ).  The follicular fluid (FF) that surrounds the cumulus-oocyte complex contains several\nfactors that originate from the blood transudate and are secreted by cumulus cells,\nsuch as proteins, steroids, polysaccharides and other metabolites; thus, FF provides\na unique microenvironment in which to study oocyte development and maturation ( Schweigert et al. , 2006 ; Appasamy et al. , 2008 )  It is recognized that the FF from women with PCOS is characterized by deregulated\nexpression of several compounds, including anti-M\u00fcllerian hormone (AMH),\ninhibin-B, activin-A, amphiregulin, heparan sulfate proteoglycan 2; tumour necrosis\nfactor (TNF), \u03b1-induced protein 6 and plasminogen ( Ambekar et al ., 2015 ). Although previous\nstudies have identified molecules in the FF of PCOS patients that are associated\nwith the deregulation of follicle maturation, this process is not completely\nunderstood. We aimed to identify putative differences in the FF profiles of PCOS\npatients and fertile women, represented by egg donors, using mass spectrometric\nanalysis to better understand the mechanisms that lead to deregulated oocyte\ndevelopment.    MATERIAL AND METHODS   Study design  This prospective study evaluated the protein components of FF from oocyte donors\n(ODs) in comparison to those of FF from infertile women with PCOS who underwent\nIVF at Huntington Reproductive Medicine Centre and the Reproductive Unit of the\nFederal University of S\u00e3o Paulo (UNIFESP) from 2012 to 2015. This study\nprotocol was approved by the ethics committee of Federal University of\nS\u00e3o Paulo (No. 1620/2011), and informed written consent was obtained from\neach patient.    Casuistic  Thirteen (13) patients were enrolled and divided into two groups: ODs (n=7) and\ninfertile PCOS patients (PCOS; n=6). The ODs were healthy female volunteers\nunder the age of 32 years with body mass indices between 18 and 30\nkg/m 2 , antral follicle counts \u226510, normal karyotypes, and\nthe absence of endometriosis who had been screened and tested for infectious\ndiseases. The PCOS patients were diagnosed with infertility according the\nRotterdam criteria ( Rotterdam\nESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004 ). All the\nPCOS patients presented body mass indices (BMI) below 25 kg/m 2 , basal\nfollicular stimulating hormone (FSH) levels below 15 IU/L, basal oestradiol\nlevels below 50 pg/mL, the presence of both ovaries, and no ongoing infectious\ndiseases or uterine abnormalities, and they had undergone intracytoplasmic sperm\ninjection (ICSI) cycles with ejaculated sperm. For both groups, patients who\npresented gynaecological bleeding, hydrosalpinx, allergy to gonadotropins or\nother medications used in the treatment, severe oligo- or azoospermia, abusive\nuse of any medications or ovarian hyperstimulation syndrome (OHSS) during the\ntreatment were excluded.    Ovarian stimulation protocol and sample collection  FF was obtained from women who underwent the standard short protocol of IVF\n(using a GnRH antagonist - Cetrotide \u00ae , Merck, Germany).\nControlled ovarian stimulation was performed using recombinant FSH (rFSH -\nGonal-F \u00ae , Merck, Germany) and was monitored with\nultrasound. Ovulation was triggered with a GnRH agonist (aGnRH - Gonapeptyl,\nFerring, Germany) when at least two follicles reached 20 mm. The FF was\ncollected from the dominant follicles through aspiration between 34 and 36 h\nafter aGnRH administration, using transvaginal ultrasound guidance. Only clear\nFF samples, without blood or flushing medium contamination, were processed. The\nselected FF samples were centrifuged at 1200 rpm for 10 to 15 min to remove\ncellular debris. The supernatants were stored at \u221280\u00baC until\npurification.    Protein extraction  Before analysis, albumin and immunoglobulins were removed from the FF samples (25\n\u00b5L) using the Albumin & IgG Depletion SpinTrap (GE Healthcare Life\nSciences\u2122) according to the manufacturer\u2019s protocol. The protein\nconcentration in each FF sample was measured in triplicate using a bicinchoninic\nacid assay (BCA assay) ( Smith et\nal ., 1985 ). Twenty-five to thirty micrograms of\nalbumin/IgG-depleted FF protein was subjected to electrophoresis via 12.5%\nsodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under\nreducing conditions ( Laemmli, 1970 ) and\nstained with Coomassie brilliant blue R-250.  All gels were analysed, and ten bands were cut equally for each sample and\nprocessed separately for in-gel digestion according to the protocol described by Westermeier et al .\n(2002) , with slight modifications.    Mass spectrometry analysis  Liquid chromatography-mass spectrometry (LC-MS) analyses were performed using an\nElectrospray-Ion Trap-Time of Flight system (ESI-IT-TOF) (Shimadzu Co., Japan)\nequipped with a binary Ultra-Fast Liquid Chromatography system (UFLC) (20A\nProminence, Shimadzu) at the Laboratory of Biochemistry and Biophysics of the\nButantan Institute (S\u00e3o Paulo, Brazil). First, each band sample was\nlyophilized, resuspended in 50 \u00b5L of 0.1% acetic acid and loaded on a C18\ncolumn (Discovery C18, 5 \u00b5m; 50 \u00d7 2.1 mm) in a binary solvent\nsystem: (A2) water/acetic acid (999/1, v/v) and (B2) ACN/water/acetic acid\n(900/99/1, v/v/v). The column was eluted at a constant flow rate of 0.2 mL.min\u22121\nwith a 5 to 70% gradient of solvent B2 over 35 min. The eluates were monitored\nby a Shimadzu SPD-M20A PDA detector before introduction into the mass\nspectrometer. The interface voltage was adjusted to 4.5 kV, and the capillary\nvoltage was 1.76 kV at 200\u00baC. MS spectra were acquired in positive mode\nand collected in the 80-2000 mass charge (m/z) range. MS/MS spectra were\ncollected in the 50-1950 m/z range. Instrument control, data acquisition, and\ndata processing were performed with LabSolutions (LCMSsolution 3.60.361 version,\nShimadzu).    Bioinformatics analysis  Proteomic analysis was performed using the Mascot Server (ion search) in house\nversion (2.4) and Peaks Studio V7 (Bioinformatics Solutions, Inc., Waterloo,\nCanada). The following parameters were adjusted for the search: parent mass and\nfragment mass error tolerance: 0.1 Da; enzyme: trypsin; fixed modification:\ncarbamidomethylation; variable modification: methionine oxidation; precursor\nmass search type: monoisotopic; max missed cleavages: 3; non-specific cleavages:\none; database: SwissProt, taxon: Homo sapiens ; peptide - 10\nlgP: \u226515; and protein - 10 lgP: \u226520. The false discovery rate\n(FDR) for peptide-spectrum matches was \u22641%.  Although each band was analysed separately in LC-MS, we performed a protein\nsearch combining all ten bands obtained from each patient. A protein was\nconsidered exclusive when it was detected in the FF of patients in either the OD\nor PCOS group and was totally absent in all of the samples from the other group;\na protein was considered overexpressed when it was detected in both groups, but\none group had a mean detected peptide level greater than that of the other group\nby 50% (greater than 1.5-fold in one group and less than 0.5-fold in the other\ngroup).    Protein identification and classification  The identified proteins were classified according to their classes, locations,\nbiological functions and processes using the PANTHER Classification System (Gene\nOntology Phylogenetic Annotation Project, Los Angeles, USA) ( Mi et al ., 2016 ). System\nbiology analysis was carried out using Ingenuity\u2122 Pathway Analysis\nsoftware (IPA\u2122, QIAGEN, Redwood, USA). The overexpressed proteins were\nselected for the analysis of canonical pathways and biological interaction\nnetworks. The biological processes were staggered according to the IPA\u2122\nKnowledge Base. The associations between the identified proteins and canonical\npathways in the database were assessed with Ingenuity\u2122 software using\nFisher's exact test (significance of p <0.01).    Statistical analysis  Clinical proteomic studies is a multistage biomarker pipeline that begin with the\nidentification of a large number of proteins in a small set of sample. This\nscreening step, as this is our study, the number of samples included was based\non the principle that a minimum number of samples considering biological and\ntechnical variation inherent in the experiment. Thus, we included a small number\nof samples and non-parametric statistic was applied.  The patients\u2019 demographic data were evaluated using descriptive statistics.\nNormality was evaluated with the Kolmogorov-Smirnov test. Non-paired continuous\ndata were compared using the Mann-Whitney test for means comparisons and paired\ndata were compared using Wilcoxon\u2019s signed-rank test. Data analyses were\nperformed using SPSS 22 (IBM SPSS Software, USA), and significance was accepted\nfor p -values \u22640.05.     RESULTS  The patients\u2019 demographics and clinical outcomes are described in Table 1 . The ovarian reserves of the patients\nin both groups had similar profiles in terms of basal FSH dosages and antral\nfollicle counts. As expected, the OD patients were younger, and the PCOS patients\nhad longer menstrual cycle intervals. The parameters related to ovarian induction\n(length, serum hormone levels, and mature (metaphase II-MII) oocytes collected) were\nsimilar between the groups, except for the amount of gonadotropin administered,\nwhich was higher in the OD group. The OD group had a higher number of top-quality\nembryos (3 rd day) than the PCOS group.   Table 1   Demographic and clinical data for the patients in the PCOS and OD groups              OD group  PCOS group  p -value      Number of samples  7  6  ----    Age (years)  24.71\u00b13.45  33.50\u00b11.38  0.0050    BMI (kg/m 2 )  24.03\u00b11.15  21.37\u00b12.02  0.0264    Menstrual cycle interval (days)  29.29\u00b11.60  50.00\u00b121.68  0.0033    Antral follicle count  14.0\u00b14.6  14.8\u00b14.8  0.7723    Basal FSH (UI/mL)  5.56\u00b11.41  5.97\u00b11.44  0.5180    Gonadotropin dose (UI)  2829.0\u00b1 494.9  1758.0\u00b11097.0  0.0513    Oocyte induction length (days)  12.0\u00b10.0  11.7\u00b11.9  0.4282    Oestradiol (E2) * (nmol/L)  3503\u00b11777  2892\u00b12474  0.7308    Progesterone (P4) * (nmol/L)  2.74\u00b11.40  2.24\u00b11.278  0.4295    MII oocytes collected  10.86\u00b12.27  13.33\u00b13.39  0.1277    Top-quality embryos (D3)  3.4\u00b114.8  2.2\u00b12.4  0.0343       *  Measured prior to oocyte collection.     The proteomic analysis of the proteins from the FF samples matched 229 proteins in\nthe SwissProt database. Forty-five (45) proteins were detected in both groups. Three\nof these shared proteins were excluded from analyses, as they were contaminants\n(trypsins and keratins), resulting in 42 proteins shared between the two groups.\nThere were 61 proteins that were exclusive to the PCOS group, and 123 proteins that\nwere exclusive to the OD group ( Supplemental Tables\nI and II ). To refine the SwissProt\nresults, only proteins that were expressed in at least two patients from each group\nwere considered. Five proteins were selected from those exclusively expressed in the\nPCOS group, and three proteins were selected from those exclusively expressed in the\nOD group ( Table 2 ).   Table 2   Proteins that were exclusively detected in at least two FF samples from\neither the PCOS or OD group              Group  SwissProt ID  Description  Peptide mean  Average mass (Da)  Patients       PCOS   Q17R60  Interphotoreceptor matrix proteoglycan 1  1.5  89387  2    Q8 WXI7  Mucin-16  1.3  2.00E +06  3    P02765  Alpha-2-HS glycoprotein  1.5  39325  2    P02774  Vitamin D-binding protein  2.0  52964  2    Q15020  S Squamous cell carcinoma antigen recognized by T-cells\n3  1.0  109935  2     OD   P43686  26S protease regulatory subunit 6B  1.5  47366  2    Q8IWI9  MAX gene-associated protein  1.0  331836  2    Q8IWI9  Transformation/transcription domain - associated\nprotein  1.0  437603  2      The differentially expressed proteins were rated and selected. Six proteins were the\nhighest occurring peptides in the PCOS group, and ten proteins were the highest\noccurring peptides in the OD group ( Table 3 ).\nThe most significant proteins, which were expressed in the FF of at least two\npatients, were the complement C3 protein, which was overexpressed in the PCOS group,\nand titin, serum albumin, complement C4-A, complement C4-B, alpha-1-acid\nglycoprotein 1 and alpha-2-macroglobulin, which were overexpressed in the OD\ngroup.   Table 3   Proteins that were differentially expressed in the FF of PCOS and OD patients\nand for which one group had at least 50% more peptides than the other             SwissProt ID  Description  Peptide\nmean  Fold change    OD  PCOS      P04004  Vitronectin  1  4  4.0    P25311  Zinc-alpha-2 glycoprotein  1  2  2.0    P98160  Basement membrane-specific heparan sulfate proteoglycan\ncore protein  1  2  2.0    Q6 V0I7  Protocadherin Fat 4  1  2  2.0    P01834  Complement factor B  4  7  1.8    P01024  Complement C3  5.3  8  1.5    Q8 WZ42  Titin  3  2  0.6    Q9C0G6  Dynein heavy chain 6, axonemal  3  2  0.6    P02768  Serum albumin  16.75  10  0.6    P0C0 L4  Complement C4-A  4  2  0.5    P0C0 L5  Complement C4-B  4  2  0.5    P02763  Alpha-1-acid glycoprotein 1  2.5  1  0.4    P01023  Alpha-2-macroglobulin  5.75  1  0.2      The proteins that were identified as exclusive or overexpressed were classified\naccording to the Gene Ontology database and analysed with respect to biological\npathways with the Ingenuity\u2122 software. Six molecular functions were\nidentified, and four of them were very similar between the two groups (GO:0005488,\nGO:0004872, GO:0005198 and GO:0003824). The PCOS patients had fewer proteins related\nto transporter activity (GO:0005215) (7.10% OD vs. 2.30% PCOS).\nAdditionally, translation regulation activity (GO:0045182) was detected only in the\nOD patients (1.80%) but was represented by only one protein.  The evaluation of protein classes resulted in nineteen different classes ( Figure 1 ). The most representative classes for\nthe OD group were cell junction, cell adhesion and transmembrane receptor\nregulatory/adaptor, which were exclusive to this group. The PCOS group presented\nmore proteins related to the oxireductase, membrane traffic protein and ligase\nclasses. The distribution of the protein classes in terms of cellular components\ndiffered between the groups: the PCOS group had more extracellular proteins, and the\nOD group had more membrane and membrane-related proteins ( Figure 2 ).    Figure 1   Chart indicating the percentages of exclusive and upregulated FF proteins\nfrom the PCOS (dark grey) and OD (light grey) groups classified\naccording to protein classes based on the Gene Ontology database       Figure 2 Chart indicating the percentages of exclusive and upregulated FF proteins\nfrom the PCOS and OD groups, classified according to cellular components\nbased on the Gene Ontology database   The biological processes associated with the detected proteins differed remarkably\nbetween the groups ( Figure 3 ). The PCOS group\nhad more proteins associated with immune process, cell localization and biological\nadhesion molecules. The OD group had more proteins associated with metabolic\nprocesses and cell component organization, suggesting that the OD group was more\nmetabolically active.    Figure 3   Chart indicating the percentages of exclusive and upregulated FF proteins\nfrom the PCOS (dark grey) and OD (light grey) groups classified\naccording to biological processes based on the Gene Ontology\ndatabase      These results were corroborated by the biological pathway analysis ( Table 4 ), as the proteins identified in the FF\nof the OD patients were related to cellular assembly and organization and cellular\nfunction and maintenance. The PCOS group had fewer proteins matched to cellular\nassembly and organization. As expected, the proteins of the OD group matched\nbiological functions related to embryo and general organism development; only two of\nthese proteins were detected in the FF of the patients in the PCOS group. The main\ncanonical pathways ( Supplemental Table III )\nfound only for the proteins in the FF from the PCOS patients were LXR/RXR activation\n( p =9.04 E -11 , overlap 7%) and FXR/RXR activation\n( p =1.67 E -10 , overlap 6.6%), which are key for the\nmetabolism of lipids, lipoproteins and glucose, reflecting the disrupted metabolism\nexhibited by PCOS patients. In addition, proteins associated with the intrinsic\n( p =1.70E -07 , overlap 22.2%) and extrinsic\n( p =1.48E -06 , overlap 13.3%) prothrombin activation\npathways were identified in the FF from the PCOS group.   Table 4   Molecular and cellular function and physiological system development and\nfunction matched to the proteins detected in the FF from PCOS and OD\npatients               PCOS  OD      p -value  Molecules  p -value  Molecules       Molecular and Cellular\nFunction     Carbohydrate Metabolism  8.43E -03 \u2013 1.94E -06  10        Lipid Metabolism  8.43E -03 \u2013 1.94E -06  11        Small Molecule Biochemistry  8.43E -03 \u2013 1.94E -06  11        Cell-To-Cell Signalling and Interaction  8.43E -03 \u2013 3.52E -06  15        Cellular Assembly and Organization  8.43E -03 \u2013 8.38E -06  24  1.19E -02 \u2013 3.89E -05  45    Cellular Function and Maintenance      1.14E -02 \u2013 3.89E -05  38    Post-Translational Modification      8.95E -03 \u2013 9.71E -05  3    Protein Degradation      9.71E -05 \u2013 9.71E -05  2    Protein Synthesis      8.95E -03 \u2013 9.71E -05  2     Physiological System Development and\nFunction     Embryonic Development  8.43E -03 \u2013 3.52E -06  14  1.14E -02 \u2013 1.94E -04  29    Haematological System Development and Function  8.43E -03 \u2013 6.08E -06  18        Hair and Skin Development and Function  5.63E -03 \u2013 7.13E -06  9        Tissue Development  8.43E -03 - 8.38E -06  21  1.24E -02 \u2013 1.94E -04  33    Renal and Urological System Development and Function  5.63E -03 \u2013 1.19E -05  10        Nervous System Development and Function      1.14E -02 \u2013 1.94E -04  22    Organ Development      1.14E -02 \u2013 1.94E -04  20    Organismal Development      11.14E -02 \u2013 1.94E -04  32        DISCUSSION  Our findings showed significantly diminished expression of proteins involved in key\nprocesses associated with oocyte competence and embryo development in PCOS patients.\nIn addition, overexpression of proteins related to oxidative stress, the immune\nresponse and lipid, lipoprotein and carbohydrate metabolism was observed in these\npatients. Although many proteomics analyses of FF have been published recently, the\nfunctional correlations among these proteins are still poorly recognized. We\nattempted to correlate the differentially expressed proteins in the FF from PCOS\npatients with physiological pathways. We believe that the observed differences may\nreflect the PCOS patients\u2019 diminished embryo quality, as this factor is directly\nreliant on oocyte characteristics.  In our study, the inflammatory pathway represented by complement C3 protein and\nvitronectin was overexpressed in the FF from the PCOS group. The augmented levels of\nthese proteins in the FF seems to be related to poor oocyte quality, potentially\nexplaining IVF failure ( Estes et\nal ., 2009 ). Additionally, excess complement cascade activation\nleads to deficiencies in vascular endothelial growth factor (VEGF) activity, which\nis essential for proper oocyte maturation ( Jarkovska et al ., 2010 ). Another marker for the disruption of\nthe inflammatory pathway in PCOS patients is the overexpression of\nalpha-2-HS-glycoprotein (fetuin-A). This protein is an acute-phase inflammatory\nregulator that is usually upregulated in OHSS ( Jarkovska et al ., 2011 ). As we excluded OHSS patients\nand applied a GnRH agonist analogue to trigger ovulation, the presence of fetuin-A\nwas not expected and may contribute to the decreased oocyte quality in those\npatients.  Moreover, the poor oocyte quality and deregulated inflammatory status of PCOS\npatients may be related to the overexpression of vitamin D-binding protein (VDBP) in\ntheir FF. VDBP was another protein found exclusively in the FF of the PCOS group,\nand according to the literature, this protein may be related to decreased\nimplantation, pregnancy ( Estes et\nal ., 2009 ), and live birth rates ( Benkhalifa et al ., 2015 ); VDBP is even more strongly\nassociated with a higher risk of miscarriages ( Kushnir et al ., 2012 ) and foetal growth restriction\n( Wookey et al .,\n2017 ).  The overexpressed coagulation pathway found in PCOS-FF, characterized by intrinsic\nand extrinsic prothrombin activation, is also linked to an inflammatory response;\nthis pathway has important roles in follicle physiology ( de Agostini, 2006 ) and may be associated with poor IVF outcomes\n( Bianchi et al .,\n2016 ).  The exclusive and overexpressed proteins in the OD group, such as 26S protease,\nalpha-1-acid glycoprotein 1 and alpha-2-macroglobulin, are correlated with a better\novarian stimulation response. The 26S protease is a highly specialized, conserved\nribonucleoprotein that facilitates assembly of proteasome complexes; this protein is\ndirectly and indirectly involved in the regulation of gene expression ( Mittenberg, 2014 ). Alpha-2-macroglobulin is\nlinked to intrinsic and extrinsic coagulation cascades and is correlated with the\ncomplement pathway ( Hanrieder et\nal. , 2009 ). The adequate regulation of coagulation and\nimmune response pathways is essential for the extracellular matrix (ECM) modelling\nthat facilitates follicular growth, ovulation and corpus luteum formation ( Kamat et al ., 1995 ; Curry & Smith, 2006 ), which may be more\neffective in fertile women.  Furthermore, PCOS is frequently associated with disrupted lipid and carbohydrate\nmetabolism ( Dumesic et al .,\n2015 ). We found some proteins in the PCOS-FF that were absent in the OD\ngroup; these proteins represented metabolic pathways, and their presence\ncorroborated previous findings ( Dai & Lu,\n2012 ; Ambekar et al .,\n2015 ). Our findings at the FF level suggest that the impairment of lipid\nand lipoprotein metabolism also occurs within a specific microenvironment, such as\nthat of infertile women with PCOS and a normal BMI. The increased inflammatory\nstatus and metabolic disruption observed through the protein composition of the FF\nfrom our PCOS patients seem to lead to a worse prognosis for oocyte viability and\nmay affect IVF outcomes. Previous studies of PCOS patients undergoing IVF treatment\nobtained a great number of oocytes but reported poor fertilization and embryo\ndevelopment rates, an outcome that may be linked to deregulated oocyte activation\nthrough a damaged microenvironment ( Jungheim et al ., 2009 ).  To find potential markers of oocyte quality, our inclusion and exclusion criteria\nwere very strict to allow us to identify markers that are exclusive to PCOS-FF\nwithout overlapping with other pathologies and conditions, such as obesity or OHSS.\nWe hypothesize that the evaluation of fetuin-A, VDBP, complement C3 and 26S protease\nexpression in the FF of PCOS patients undergoing IVF could be associated with oocyte\nquality. The limitations of these findings include the absence of experimental\nvalidation of the candidate markers through other techniques, such as Western\nblotting; additionally, the differentially expressed proteins must be correlated\nwith the final IVF outcomes to endorse their use in clinical practice.",
    "tables": [
        {
            "title": "No Title",
            "content": "OD group  PCOS group  p -value      Number of samples  7  6  ----    Age (years)  24.71\u00b13.45  33.50\u00b11.38  0.0050    BMI (kg/m 2 )  24.03\u00b11.15  21.37\u00b12.02  0.0264    Menstrual cycle interval (days)  29.29\u00b11.60  50.00\u00b121.68  0.0033    Antral follicle count  14.0\u00b14.6  14.8\u00b14.8  0.7723    Basal FSH (UI/mL)  5.56\u00b11.41  5.97\u00b11.44  0.5180    Gonadotropin dose (UI)  2829.0\u00b1 494.9  1758.0\u00b11097.0  0.0513    Oocyte induction length (days)  12.0\u00b10.0  11.7\u00b11.9  0.4282    Oestradiol (E2) * (nmol/L)  3503\u00b11777  2892\u00b12474  0.7308    Progesterone (P4) * (nmol/L)  2.74\u00b11.40  2.24\u00b11.278  0.4295    MII oocytes collected  10.86\u00b12.27  13.33\u00b13.39  0.1277    Top-quality embryos (D3)  3.4\u00b114.8  2.2\u00b12.4  0.0343"
        },
        {
            "title": "No Title",
            "content": "Group  SwissProt ID  Description  Peptide mean  Average mass (Da)  Patients       PCOS   Q17R60  Interphotoreceptor matrix proteoglycan 1  1.5  89387  2    Q8 WXI7  Mucin-16  1.3  2.00E +06  3    P02765  Alpha-2-HS glycoprotein  1.5  39325  2    P02774  Vitamin D-binding protein  2.0  52964  2    Q15020  S Squamous cell carcinoma antigen recognized by T-cells\n3  1.0  109935  2     OD   P43686  26S protease regulatory subunit 6B  1.5  47366  2    Q8IWI9  MAX gene-associated protein  1.0  331836  2    Q8IWI9  Transformation/transcription domain - associated\nprotein  1.0  437603  2"
        },
        {
            "title": "No Title",
            "content": "SwissProt ID  Description  Peptide\nmean  Fold change    OD  PCOS      P04004  Vitronectin  1  4  4.0    P25311  Zinc-alpha-2 glycoprotein  1  2  2.0    P98160  Basement membrane-specific heparan sulfate proteoglycan\ncore protein  1  2  2.0    Q6 V0I7  Protocadherin Fat 4  1  2  2.0    P01834  Complement factor B  4  7  1.8    P01024  Complement C3  5.3  8  1.5    Q8 WZ42  Titin  3  2  0.6    Q9C0G6  Dynein heavy chain 6, axonemal  3  2  0.6    P02768  Serum albumin  16.75  10  0.6    P0C0 L4  Complement C4-A  4  2  0.5    P0C0 L5  Complement C4-B  4  2  0.5    P02763  Alpha-1-acid glycoprotein 1  2.5  1  0.4    P01023  Alpha-2-macroglobulin  5.75  1  0.2"
        },
        {
            "title": "No Title",
            "content": "PCOS  OD      p -value  Molecules  p -value  Molecules       Molecular and Cellular\nFunction     Carbohydrate Metabolism  8.43E -03 \u2013 1.94E -06  10        Lipid Metabolism  8.43E -03 \u2013 1.94E -06  11        Small Molecule Biochemistry  8.43E -03 \u2013 1.94E -06  11        Cell-To-Cell Signalling and Interaction  8.43E -03 \u2013 3.52E -06  15        Cellular Assembly and Organization  8.43E -03 \u2013 8.38E -06  24  1.19E -02 \u2013 3.89E -05  45    Cellular Function and Maintenance      1.14E -02 \u2013 3.89E -05  38    Post-Translational Modification      8.95E -03 \u2013 9.71E -05  3    Protein Degradation      9.71E -05 \u2013 9.71E -05  2    Protein Synthesis      8.95E -03 \u2013 9.71E -05  2     Physiological System Development and\nFunction     Embryonic Development  8.43E -03 \u2013 3.52E -06  14  1.14E -02 \u2013 1.94E -04  29    Haematological System Development and Function  8.43E -03 \u2013 6.08E -06  18        Hair and Skin Development and Function  5.63E -03 \u2013 7.13E -06  9        Tissue Development  8.43E -03 - 8.38E -06  21  1.24E -02 \u2013 1.94E -04  33    Renal and Urological System Development and Function  5.63E -03 \u2013 1.19E -05  10        Nervous System Development and Function      1.14E -02 \u2013 1.94E -04  22    Organ Development      1.14E -02 \u2013 1.94E -04  20    Organismal Development      11.14E -02 \u2013 1.94E -04  32"
        },
        {
            "title": "No Title",
            "content": "SwissProt ID  Name  Class  Molecular Function  Cellular compartment  Number of Patients      Q17R60  Interphotoreceptor matrix proteoglycan 1  Glicoprote\u00edna de matriz extracelular\n(PC00102); receptor (PC00100)  receptor activity(GO:0004872)  extracellular region(GO:0005576)  3    Q8WXI7  Mucin-16  NA  NA  NA  3    PNA1NA42  Complement C3  NA  cysteine-type endopeptidase inhibitor\nactivity(GO:0003824)  #N/D  2    P02765  Alpha-2-HS-glycoprotein  Inibidor de ciste\u00edna protease (PC00095);\nGlicoprote\u00edna de matriz extracelular (PC00191)  peptidase inhibitor activity(GO:0003824)  extracellular space(GO:0005576)  2    P02774  Vitamin D-binding protein  NA  NA  NA  2    Q15020  Squamous cell carcinoma antigen recognized by\nT-cells 3  NA  NA  NA  2    A6NDX4  Putative transmembrane protein  NA  NA  #N/D  1    O14526  FCH domain only protein 1  Prote\u00edna de citoesqueleto da\nfam\u00edlia das actinas (PC00085); prote\u00edna reguladora\nde trafficking de membrana (PC00041)  NA  NA  1    O14578  Citron Rho-interacting kinase  non-receptor serine/threonine protein\nkinase(PC00220)  protein kinase activity(GO:0003824)  NA  1    O15020  Spectrin beta chain, non-erythrocytic 2  non-motor actin binding protein(PC00085)  actin binding(GO:0005488);structural constituent\nof cytoskeleton(GO:0005515)  intracellular(GO:0044464)  1    O15357  Phosphatidylinositol 3,4,5-trisphosphate\n5-phosphatase 2  phosphatase(PC00121)  NA  NA  1    O75445  Usherin  extracellular matrix linker\nprotein(PC00102);receptor(PC00101)  receptor activity(GO:0004872)  extracellular matrix(GO:0031012);extracellular\nregion(GO:0005576)  1    O75691  Small subunit processome component 20\nhomolog  NA  NA  intracellular(GO:0044464);nucleolus(GO:0005622);ribonucleoprotein\ncomplex(GO:0043226)  1    P00739  Haptoglobin-related protein  annexin(PC00060);calmodulin(PC00050);peptide\nhormone(PC00131);protease\ninhibitor(PC00061);receptor(PC00207);serine\nprotease(PC00179)  NA  NA  1    P01008  Antithrombin-III  serine protease inhibitor(PC00095)  serine-type endopeptidase inhibitor\nactivity(GO:0003824);serine-type peptidase\nactivity(GO:0016787)  extracellular space(GO:0005576)  1    P01019  Angiotensinogen  serine protease inhibitor(PC00095)  serine-type endopeptidase inhibitor\nactivity(GO:0003824);serine-type peptidase\nactivity(GO:0016787)  extracellular space(GO:0005576)  1    P02538  Keratin, type II cytoskeletal 6A  intermediate filament(PC00085);structural\nprotein(PC00129)  structural constituent of\ncytoskeleton(GO:0005198)  intermediate filament\ncytoskeleton(GO:0043226);intracellular(GO:0005856)  1    P02671  Fibrinogen alpha chain  signaling molecule(PC00207)  receptor binding(GO:0005488)  extracellular region(GO:0005576)  1    P02675  Fibrinogen beta chain  signaling molecule(PC00207)  receptor binding(GO:0005488)  extracellular region(GO:0005576)  1    P02679  Fibrinogen gamma chain  NA  NA  NA  1    P02790  Hemopexin  transfer/carrier protein(PC00219)  NA  extracellular matrix(GO:0031012)  1    P04259  Keratin, type II cytoskeletal 6B  intermediate filament(PC00085);structural\nprotein(PC00129)  structural constituent of\ncytoskeleton(GO:0005198)  intermediate filament\ncytoskeleton(GO:0043226);intracellular(GO:0005856)  1    P08574  Cytochrome c1, heme protein, mitochondrial  NA  NA  cytoplasm(GO:0044464);mitochondrion(GO:0005622)      P08603  Complement factor H  NA  NA  NA  1    P09529  Inhibin beta B chain  growth factor(PC00207)  transforming growth factor beta receptor\nbinding(GO:0005488)  extracellular space(GO:0005576)  1    P13645  Keratin, type I cytoskeletal 10  intermediate filament(PC00085);structural\nprotein(PC00129)  structural constituent of\ncytoskeleton(GO:0005198)  intermediate filament\ncytoskeleton(GO:0043226);intracellular(GO:0005856)  1    P19827  Inter-alpha-trypsin inhibitor heavy chain H1  serine protease inhibitor(PC00095)  protein binding(GO:0005488);serine-type\nendopeptidase inhibitor activity(GO:0005515)  NA  1    P20742  Pregnancy zone protein  complement\ncomponent(PC00090);cytokine(PC00078);serine protease\ninhibitor(PC00207)  cytokine activity(GO:0005488);serine-type\nendopeptidase inhibitor activity(GO:0005515)  NA  1    P27169  Serum paraoxonase/arylesterase 1  NA  hydrolase activity, acting on ester\nbonds(GO:0003824)  NA  1    P33991  DNA replication licensing factor MCM4  DNA helicase(PC00171);hydrolase(PC00009)  DNA helicase activity(GO:0003824);hydrolase\nactivity(GO:0004386);nucleic acid binding(GO:0003678)  NA  1    P35908  Keratin, type II cytoskeletal 2 epidermal  intermediate filament(PC00085);structural\nprotein(PC00129)  structural constituent of\ncytoskeleton(GO:0005198)  intermediate filament\ncytoskeleton(GO:0043226);intracellular(GO:0005856)  1    P48668  Keratin, type II cytoskeletal 6C  intermediate filament(PC00085);structural\nprotein(PC00129)  structural constituent of\ncytoskeleton(GO:0005198)  intermediate filament\ncytoskeleton(GO:0043226);intracellular(GO:0005856)  1    P49454  Centromere protein F  NA  NA  NA  1    P49589  Cysteine--tRNA ligase, cytoplasmic  RNA binding protein(PC00171);aminoacyl-tRNA\nsynthetase(PC00031)  aminoacyl-tRNA ligase activity(GO:0003824)  cytosol(GO:0044464)  1    P49842  Serine/threonine-protein kinase 19  NA  NA  NA  1    P78312  Protein FAM193A  NA  NA  NA  1    P98170  E3 ubiquitin-protein ligase XIAP  protease inhibitor(PC00095)  cysteine-type endopeptidase inhibitor\nactivity(GO:0003824);ubiquitin-protein ligase\nactivity(GO:0016787)  cytoplasm(GO:0044464);microtubule(GO:0005622);nucleus(GO:0005737)  1    Q12873  Chromodomain-helicase-DNA-binding protein 3  DNA helicase(PC00171)  NA  NA  1    Q13129  Zinc finger protein Rlf  nuclease(PC00171);transcription\nfactor(PC00170)  nuclease activity(GO:0003824);sequence-specific\nDNA binding transcription factor activity(GO:0016787)  NA  1    Q15813  Tubulin-specific chaperone E  chaperone(PC00072)  NA  NA  1    Q3KP22  Uncharacterized protein C11orf85  NA  NA  NA  1    Q53GS7  Nucleoporin GLE1  nucleic acid binding(PC00171);transfer/carrier\nprotein(PC00219)  nucleic acid binding(GO:0005488)  NA  1    Q63HN8  E3 ubiquitin-protein ligase RNF213  NA  NA  NA  1    Q6YP21  Kynurenine--oxoglutarate transaminase 3  transaminase(PC00220)  transaminase activity(GO:0003824)  NA  1    Q70CQ2  Ubiquitin carboxyl-terminal hydrolase 34  NA  NA  NA  1    Q7Z6M1  Rab9 effector protein with kelch motifs  NA  NA  NA  1    Q86YQ8  Copine-8  membrane traffic protein(PC00150)  NA  NA  1    Q8IWT3  Cullin-9  NA  NA  NA  1    Q8IY50  Putative thiamine transporter SLC35F3  NA  NA  NA  1    Q8N9W7  Putative transmembrane protein FLJ36131  NA  #N/D  #N/D  1    Q8NHM4  Putative trypsin-6  serine protease(PC00121)  serine-type peptidase activity(GO:0003824)  extracellular space(GO:0005576)  1    Q8TDI0  Chromodomain-helicase-DNA-binding protein 5  DNA helicase(PC00171)  NA  NA  1    Q8TF01  Arginine/serine-rich protein PNISR  NA  NA  NA  1    Q92665  28S ribosomal protein S31, mitochondrial  NA  NA  NA  1    Q9H1H9  Kinesin-like protein KIF13A  microtubule binding motor protein(PC00085)  microtubule motor activity(GO:0003824)  cytoskeleton(GO:0043226);intracellular(GO:0005856);protein\ncomplex(GO:0044464)  1    Q9NQ66  1-phosphatidylinositol 4,5-bisphosphate\nphosphodiesterase beta-1  calcium-binding\nprotein(PC00060);guanyl-nucleotide exchange\nfactor(PC00095);phospholipase(PC00022);signaling\nmolecule(PC00113)  calcium ion binding(GO:0005488);guanyl-nucleotide\nexchange factor activity(GO:0005509);phospholipase\nactivity(GO:0003824);receptor binding(GO:0030234);small GTPase\nregulator activity(GO:0005085)  NA  1    Q9NTG1  Polycystic kidney disease and receptor for egg\njelly-related protein  G-protein modulator(PC00095);ion\nchannel(PC00022);membrane-bound signaling molecule(PC00227)  Cation channel activity(GO:0005215)  NA  1    Q9P212  1-phosphatidylinositol 4,5-bisphosphate\nphosphodiesterase epsilon-1  calcium-binding\nprotein(PC00060);guanyl-nucleotide exchange\nfactor(PC00095);phospholipase(PC00022);signaling\nmolecule(PC00113)  calcium ion binding(GO:0005488);guanyl-nucleotide\nexchange factor activity(GO:0005509);phospholipase\nactivity(GO:0003824);receptor binding(GO:0030234);small GTPase\nregulator activity(GO:0005085)  NA  1    Q9P225  Dynein heavy chain 2, axonemal  hydrolase(PC00121);microtubule binding motor\nprotein(PC00085)  microtubule motor activity(GO:0003824);structural\nconstituent of cytoskeleton(GO:0016787)  intracellular(GO:0044464);microtubule(GO:0005622)  1    Q9P2N5  RNA-binding protein 27  RNA binding protein(PC00171)  RNA binding(GO:0005488)  NA  1    Q9UKA4  RNA-binding protein 27  kinase modulator(PC00095)  protein binding(GO:0005488)  cytoplasm(GO:0044464)  1"
        },
        {
            "title": "No Title",
            "content": "SwissProt ID  Name  Class  Molecular Function  Cellular compartment  Number of Patients      P43686  26S protease regulatory subunit 6B  hydrolase(PC00121)  protein binding(GO:0005488)  cytosol(GO:0044464);nucleus(GO:0005622);protein\ncomplex(GO:0005737)  2    Q8IWI9  MAX gene-associated protein  nucleic acid binding(PC00171);transcription\nfactor(PC00218)  sequence-specific DNA binding transcription\nfactor activity(GO:0005488)  NA  2    Q9Y4A5  Transformation/transcription domain-associated\nprotein  non-receptor serine/threonine protein\nkinase(PC00220);nucleotide kinase(PC00137)  kinase activity(GO:0003824)  NA  2    A0AUZ9  KAT8 regulatory NSL complex subunit 1-like\nprotein  NA  NA  NA  1    A5PLK6  Regulator of G-protein signaling\nprotein-like  G-protein modulator(PC00095)  GTPase activity(GO:0003824);enzyme activator\nactivity(GO:0016787);pyrophosphatase activity(GO:0003924)  cytoplasm(GO:0044464);plasma\nmembrane(GO:0005622)  1    A6NJZ7  RIMS-binding protein 3C  NA  NA  NA  1    A6NNM3  RIMS-binding protein 3B  NA  NA  NA  1    O00268  Transcription initiation factor TFIID subunit\n4  NA  NA  NA  1    O14641  Segment polarity protein dishevelled homolog\nDVL-2  enzyme modulator(PC00095);signaling\nmolecule(PC00207)  receptor binding(GO:0005488)  cytosol(GO:0044464)  1    O14948  Transcription factor EC  basic helix-loop-helix transcription\nfactor(PC00218)  NA  NA  1    O15294  UDP-N-acetylglucosamine--peptide\nN-acetylglucosaminyltransferase 110 kDa subunit  glycosyltransferase(PC00220)  transferase activity, transferring glycosyl\ngroups(GO:0003824)  NA  1    O43187  Interleukin-1 receptor-associated kinase-like\n2  NA  protein kinase activity(GO:0003824)  cytoplasm(GO:0044464);nucleus(GO:0005622)  1    O43451  Maltase-glucoamylase, intestinal  glucosidase(PC00121)  glucosidase activity(GO:0003824)  NA  1    O60229  Kalirin  guanyl-nucleotide exchange\nfactor(PC00095);signaling molecule(PC00022)  guanyl-nucleotide exchange factor\nactivity(GO:0003824);receptor binding(GO:0030234);small GTPase\nregulator activity(GO:0005085)  NA  1    O60318  Germinal-center associated nuclear protein  ATP synthase(PC00227);hydrolase(PC00068)  cation transmembrane transporter\nactivity(GO:0005215);hydrogen ion transmembrane transporter\nactivity(GO:0022857);hydrolase activity(GO:0008324)  NA  1    O60494  Cubilin  apolipoprotein(PC00219);cell adhesion\nmolecule(PC00052);enzyme modulator(PC00069);extracellular matrix\nprotein(PC00095);membrane-bound signaling\nmolecule(PC00102);metalloprotease(PC00207);oxidase(PC00152);serine\nprotease(PC00121);transporter(PC00190)  enzyme regulator activity(GO:0003824);lipid\ntransporter activity(GO:0030234);metallopeptidase\nactivity(GO:0005215);oxidoreductase\nactivity(GO:0005319);receptor activity(GO:0016787);serine-type\npeptidase activity(GO:0008233);transmembrane transporter\nactivity(GO:0008237)  extracellular matrix(GO:0031012);extracellular\nregion(GO:0005576)  1    O75094  Slit homolog 3 protein  NA  NA  NA  1    O75901  Ras association domain-containing protein 9  membrane traffic protein(PC00150)  NA  NA  1    O94813  Slit homolog 2 protein  NA  NA  NA  1    O95206  Protocadherin-8  cadherin(PC00069)  calcium ion binding(GO:0005488)  NA  1    O95490  Latrophilin-2  G-protein coupled receptor(PC00197);antibacterial\nresponse protein(PC00021)  receptor activity(GO:0004872)  NA  1    O95613  Pericentrin  chromatin/chromatin-binding\nprotein(PC00171);hydrolase(PC00009);kinase\nmodulator(PC00077)  chromatin binding(GO:0005488);hydrolase\nactivity(GO:0003682);kinase regulator\nactivity(GO:0003824);nucleic acid binding(GO:0016787);protein\nbinding(GO:0016740)  NA  1    O95661  GTP-binding protein Di-Ras3  small GTPase(PC00095)  GTPase activity(GO:0003824);protein\nbinding(GO:0016787)  NA  1    O95835  Serine/threonine-protein kinase LATS1  annexin(PC00060);calmodulin(PC00050);non-receptor\nserine/threonine protein kinase(PC00131);transfer/carrier\nprotein(PC00061)  protein kinase activity(GO:0003824)  intracellular(GO:0044464)  1    O95947  T-box transcription factor TBX6  nucleic acid binding(PC00171);transcription\nfactor(PC00218)  sequence-specific DNA binding transcription\nfactor activity(GO:0005488)  NA  1    P01857  Ig gamma-1 chain C region  NA  antigen binding(GO:0005488);receptor\nbinding(GO:0003823)  extracellular space(GO:0005576);immunoglobulin\ncomplex(GO:0005615);plasma membrane(GO:0032991)  1    P06396  Gelsolin  non-motor actin binding protein(PC00085)  actin binding(GO:0005488);structural constituent\nof cytoskeleton(GO:0005515)  actin\ncytoskeleton(GO:0043226);intracellular(GO:0005856)  1    P07333  Macrophage colony-stimulating factor 1\nreceptor  NA  NA  NA  1    P0C7U3  Probable palmitoyltransferase ZDHHC11B  NA  NA  NA  1    P13761  HLA class II histocompatibility antigen, DRB1-7\nbeta chain  #N/D  #N/D  #N/D  1    P35527  Keratin, type I cytoskeletal 9  intermediate filament(PC00085);structural\nprotein(PC00129)  structural constituent of\ncytoskeleton(GO:0005198)  intermediate filament\ncytoskeleton(GO:0043226);intracellular(GO:0005856)  1    P42345  Serine/threonine-protein kinase mT  non-receptor serine/threonine protein\nkinase(PC00220);nucleotide kinase(PC00137)  kinase activity(GO:0003824)  NA  1    P46013  Antigen KI-67  NA  NA  NA  1    P49750  YLP motif-containing protein 1  nucleic acid binding(PC00171)  nucleic acid binding(GO:0005488)  NA  1    P49792  E3 SUM  G-protein modulator(PC00095)  protein binding(GO:0005488);small GTPase\nregulator activity(GO:0005515)  NA  1    P51805  Plexin-A3  signaling molecule(PC00207);tyrosine protein\nkinase receptor(PC00197)  NA  NA  1    P98161  Polycystin-1  G-protein modulator(PC00095);ion\nchannel(PC00022);membrane-bound signaling molecule(PC00227)  cation channel activity(GO:0005215)  NA  1    Q04637  Eukaryotic translation initiation factor 4 gamma\n1  translation initiation factor(PC00171)  translation initiation factor\nactivity(GO:0045182)  NA  1    Q08170  Serine/arginine-rich splicing factor 4  NA  NA  NA  1    Q08AE8  Protein spire homolog 1  actin family cytoskeletal protein(PC00085)  structural constituent of\ncytoskeleton(GO:0005198)  intracellular(GO:0044464)  1    Q13402  Unconventional myosin-VIIa  G-protein modulator(PC00095);actin binding motor\nprotein(PC00022);cell junction protein(PC00085)  enzyme regulator activity(GO:0003824);motor\nactivity(GO:0030234);protein binding(GO:0016787);structural\nconstituent of cytoskeleton(GO:0016462)  actin\ncytoskeleton(GO:0043226);intracellular(GO:0005856);plasma\nmembrane(GO:0015629)  1    Q13563  Polycystin-2  G-protein modulator(PC00095);ion\nchannel(PC00022);membrane-bound signaling molecule(PC00227)  cation channel activity(GO:0005215)  NA  1    Q14643  Inositol 1,4,5-trisphosphate receptor type 1  ligand-gated ion channel(PC00227)  ligand-gated ion channel\nactivity(GO:0005215);receptor activity(GO:0022857)  NA  1    Q14980  Nuclear mitotic apparatus protein 1  NA  NA  NA  1    Q15149  Plectin  non-motor actin binding protein(PC00085)  actin binding(GO:0005488);structural constituent\nof cytoskeleton(GO:0005515)  actin\ncytoskeleton(GO:0043226);intracellular(GO:0005856)  1    Q15413  Ryanodine receptor 3  ligand-gated ion channel(PC00227)  ligand-gated ion channel\nactivity(GO:0005215);receptor activity(GO:0022857)  NA  1    Q15772  Striated muscle preferentially expressed protein\nkinase  G-protein coupled\nreceptor(PC00197);immunoglobulin receptor\nsuperfamily(PC00021);immunoglobulin superfamily cell adhesion\nmolecule(PC00090);protein phosphatase(PC00124)  NA  NA  1    Q16531  DNA damage-binding protein 1  damaged DNA-binding protein(PC00171);mRNA\npolyadenylation factor(PC00009)  damaged DNA binding(GO:0005488)  intracellular(GO:0044464);nucleus(GO:0005622);protein\ncomplex(GO:0043226)  1    Q2LD37  Uncharacterized protein KIAA1109  NA  NA  NA  1    Q3B7T1  Erythroid differentiation-related factor 1  NA  NA  NA  1    Q460N5  Poly [ADP-ribose] polymerase\n14  nucleic acid binding(PC00171)  nucleic acid binding(GO:0005488)  NA  1    Q562E7  WD repeat-containing protein 81  esterase(PC00121);kinase inhibitor(PC00097);mRNA\nsplicing factor(PC00095)  NA  NA  1    Q5JSL3  Dedicator of cytokinesis protein 11  guanyl-nucleotide exchange factor(PC00095)  guanyl-nucleotide exchange factor\nactivity(GO:0003824);small GTPase regulator\nactivity(GO:0030234)  NA  1    Q5T5C0  Syntaxin-binding protein 5  membrane trafficking regulatory\nprotein(PC00150)  GTPase activity(GO:0003824);enzyme activator\nactivity(GO:0016787);pyrophosphatase activity(GO:0003924)  cytoplasm(GO:0044464);plasma\nmembrane(GO:0005622)  1    Q5TC82  Roquin-1  NA  NA  NA  1    Q5TZA2  Rootletin  kinase modulator(PC00095);viral\nprotein(PC00140)  kinase regulator activity(GO:0003824);protein\nbinding(GO:0016740)  NA  1    Q5UIP0  Telomere-associated protein RIF1  NA  NA  NA  1    Q5VST9  Obscurin  immunoglobulin receptor\nsuperfamily(PC00090);immunoglobulin superfamily cell adhesion\nmolecule(PC00124);protein phosphatase(PC00069)  NA  NA  1    Q5VT52  Regulation of nuclear pre-mRNA domain-containing\nprotein 2  kinase inhibitor(PC00095)  kinase inhibitor activity(GO:0003824);protein\nbinding(GO:0030234)  NA  1    Q5VUA4  Zinc finger protein 318  NA  NA  NA  1    Q5VYK3  Proteasome-associated protein ECM29 homolog  kinase modulator(PC00095)  kinase regulator activity(GO:0003824);protein\nbinding(GO:0016740)  NA  1    Q5VZM2  Ras-related GTP-binding protein B  small GTPase(PC00095)  GTPase activity(GO:0003824);pyrophosphatase\nactivity(GO:0016787)  cytoplasm(GO:0044464);endosome(GO:0005622);lysosome(GO:0005737);membrane(GO:0043226);protein\ncomplex(GO:0005768);vacuole(GO:0005764)  1    Q66K64  DDB1- and CUL4-associated factor 15  NA  NA  NA  1    Q6P9F0  Coiled-coil domain-containing protein 62  #N/D  #N/D  #N/D  1    Q6ZN55  Zinc finger protein 574  KRAB box transcription factor(PC00218)  NA  NA  1    Q6ZT12  E3 ubiquitin-protein ligase UBR3  NA  NA  cytoplasm(GO:0044464);protein\ncomplex(GO:0005622)  1    Q6ZV29  Patatin-like phospholipase domain-containing\nprotein 7  esterase(PC00121)  phospholipase activity(GO:0003824)  cytoplasm(GO:0044464);endoplasmic\nreticulum(GO:0005622)  1    Q70JA7  Chondroitin sulfate synthase 3  glycosyltransferase(PC00220)  transferase activity, transferring glycosyl\ngroups(GO:0003824)  NA  1    Q7L523  Ras-related GTP-binding protein A  small GTPase(PC00095)  GTPase activity(GO:0003824);pyrophosphatase\nactivity(GO:0016787)  cytoplasm(GO:0044464);endosome(GO:0005622);lysosome(GO:0005737);membrane(GO:0043226);protein\ncomplex(GO:0005768);vacuole(GO:0005764)  1    Q7Z494  Nephrocystin-3  NA  NA  microtubule(GO:0043226)  1    Q7Z794  Keratin, type II cytoskeletal 1b  intermediate filament(PC00085);structural\nprotein(PC00129)  structural constituent of\ncytoskeleton(GO:0005198)  intermediate filament\ncytoskeleton(GO:0043226);intracellular(GO:0005856)  1    Q7Z7G8  Vacuolar protein sorting-associated protein\n13B  NA  NA  NA  1    Q7Z7M0  Multiple epidermal growth factor-like domains\nprotein 8  extracellular matrix linker\nprotein(PC00102);receptor(PC00101);small GTPase(PC00197)  GTPase activity(GO:0003824);receptor\nactivity(GO:0016787)  extracellular matrix(GO:0031012);extracellular\nregion(GO:0005576)  1    Q86TS7  Putative UPF0730 protein encoded by\nLINC00643  NA  NA  NA  1    Q8IVE3  Pleckstrin homology domain-containing family H\nmember 2  NA  NA  NA  1    Q8IYF3  Testis-expressed sequence 11 protein  chaperone(PC00072)  NA  NA  1    Q8IZD9  Dedicator of cytokinesis protein 3  guanyl-nucleotide exchange factor(PC00095)  guanyl-nucleotide exchange factor\nactivity(GO:0003824);small GTPase regulator\nactivity(GO:0030234)  NA  1    Q8N3S3  Putative homeodomain transcription factor 2  homeobox transcription factor(PC00218);nucleic\nacid binding(PC00116)  sequence-specific DNA binding transcription\nfactor activity(GO:0005488)  NA  1    Q8N4F7  RING finger protein 175  ubiquitin-protein ligase(PC00142)  NA  Golgi\napparatus(GO:0043226);cytoplasm(GO:0005794);endoplasmic\nreticulum(GO:0044464);nuclear outer membrane-endoplasmic\nreticulum membrane network(GO:0005622)  1    Q8N4S9  MARVEL domain-containing protein 2  tight junction(PC00070);transcription\ncofactor(PC00214)  sequence-specific DNA binding transcription\nfactor activity(GO:0005488);transcription cofactor\nactivity(GO:0003676)  plasma membrane(GO:0016020)  1    Q8N554  Zinc finger protein 276  NA  NA  NA  1    Q8N8Z8  Zinc finger protein 441  NA  NA  NA  1    Q8NA56  Tetratricopeptide repeat protein 29  guanyl-nucleotide exchange\nfactor(PC00095);transmembrane receptor regulatory/adaptor\nprotein(PC00022)  guanyl-nucleotide exchange factor\nactivity(GO:0003824);small GTPase regulator\nactivity(GO:0030234)  NA  1    Q8NE71  ATP-binding cassette sub-family F member 1  ATP-binding cassette (ABC)\ntransporter(PC00227);hydrolase(PC00003);translation elongation\nfactor(PC00121)  ATPase activity, coupled to transmembrane\nmovement of substances(GO:0003824);translation elongation factor\nactivity(GO:0016787);transmembrane transporter\nactivity(GO:0042626)  NA  1    Q8NEZ4  Histone-lysine N-methyltransferase 2C  DNA binding\nprotein(PC00171);methyltransferase(PC00009)  NA  NA  1    Q8NF91  Nesprin-1  non-motor actin binding protein(PC00085)  actin binding(GO:0005488);structural constituent\nof cytoskeleton(GO:0005515)  intracellular(GO:0044464)  1    Q8NFC6  Biorientation of chromosomes in cell division\nprotein 1-like 1  NA  NA  NA  1    Q8NG31  Protein CASC5  NA  NA  NA  1    Q8NI35  InaD-like protein  NA  NA  NA  1    Q8TER5  Rho guanine nucleotide exchange factor 40  guanyl-nucleotide exchange\nfactor(PC00095);signaling molecule(PC00022)  guanyl-nucleotide exchange factor\nactivity(GO:0003824);receptor binding(GO:0030234);small GTPase\nregulator activity(GO:0005085)  NA  1    Q8WVC0  RNA polymerase-associated protein LE  DNA-directed RNA polymerase(PC00171)  NA  intracellular(GO:0044464);nucleus(GO:0005622)  1    Q8WWG9  Potassium voltage-gated channel subfamily E\nmember 4  NA  NA  NA  1    Q92823  Neuronal cell adhesion molecule  G-protein coupled\nreceptor(PC00197);immunoglobulin receptor\nsuperfamily(PC00021);immunoglobulin superfamily cell adhesion\nmolecule(PC00090);protein phosphatase(PC00124)  NA  NA  1    Q969F9  Hermansky-Pudlak syndrome 3 protein  NA  NA  NA  1    Q969V4  Tektin-1  NA  NA  NA  1    Q96B21  Transmembrane protein 45B  NA  NA  NA  1    Q96ID5  Immunoglobulin superfamily member 21  immunoglobulin receptor\nsuperfamily(PC00090);immunoglobulin superfamily cell adhesion\nmolecule(PC00124);protein phosphatase(PC00069)  NA  NA  1    Q96MB7  Putative nuclease HARBI1  NA  NA  NA  1    Q96NH3  Protein broad-minded  NA  NA  NA  1    Q96PX9  Pleckstrin homology domain-containing family G\nmember 4B  guanyl-nucleotide exchange\nfactor(PC00095);signaling molecule(PC00022)  guanyl-nucleotide exchange factor\nactivity(GO:0003824);receptor binding(GO:0030234);small GTPase\nregulator activity(GO:0005085)  NA  1    Q9BQ52  Zinc phosphodiesterase ELAC protein 2  NA  endoribonuclease activity(GO:0003824)  NA  1    Q9BSC4  Nucleolar protein 10  NA  NA  NA  1    Q9GIY3  HLA class II histocompatibility antigen, DRB1-14\nbeta chain  #N/D  #N/D  #N/D  1    Q9GZQ4  Neuromedin-U receptor 2  G-protein coupled receptor(PC00197)  receptor activity(GO:0004872)  NA  1    Q9H0X9  Oxysterol-binding protein-related protein 5  NA  NA  NA  1    Q9H1A4  Anaphase-promoting complex subunit 1  ligase(PC00142)  ligase activity(GO:0003824)  NA  1    Q9H254  Spectrin beta chain, non-erythrocytic 4  non-motor actin binding protein(PC00085)  actin binding(GO:0005488);structural constituent\nof cytoskeleton(GO:0005515)  intracellular(GO:0044464)  1    Q9H7M6  Zinc finger SWIM domain-containing protein 4  NA  NA  NA  1    Q9NRL2  Bromodomain adjacent to zinc finger domain\nprotein 1A  acetyltransferase(PC00220);chromatin/chromatin-binding\nprotein(PC00038)  acetyltransferase activity(GO:0003824);chromatin\nbinding(GO:0016740);nucleic acid binding(GO:0016746)  NA  1    Q9NZC2  Bromodomain adjacent to zinc finger domain\nprotein 1A  immunoglobulin receptor superfamily(PC00090)  receptor activity(GO:0004872)  NA  1    Q9P107  GEM-interacting protein  NA  NA  NA  1    Q9P227  Rho GTPase-activating protein 23  NA  GTPase activity(GO:0003824);enzyme activator\nactivity(GO:0016787);pyrophosphatase activity(GO:0003924)  NA  1    Q9UFD9  RIMS-binding protein 3A  NA  NA  NA  1    Q9UFH2  Dynein heavy chain 17, axonemal  hydrolase(PC00121);microtubule binding motor\nprotein(PC00085)  microtubule motor activity(GO:0003824);structural\nconstituent of cytoskeleton(GO:0016787)  intracellular(GO:0044464);microtubule(GO:0005622)  1    Q9UGM6  Tryptophan--tRNA ligase, mitochondrial  NA  NA  cytoplasm(GO:0044464)  1    Q9UHT4  Putative uncharacterized protein PR  #N/D  #N/D  #N/D  1    Q9UKN7  Unconventional myosin-XV  G-protein modulator(PC00095);actin binding motor\nprotein(PC00022);cell junction protein(PC00085)  enzyme regulator activity(GO:0003824);motor\nactivity(GO:0030234);protein binding(GO:0016787);structural\nconstituent of cytoskeleton(GO:0016462)  actin\ncytoskeleton(GO:0043226);intracellular(GO:0005856);plasma\nmembrane(GO:0015629)  1    Q9ULL8  Protein Shroom4  ligand-gated ion channel(PC00227)  ligand-gated ion channel\nactivity(GO:0005215);receptor activity(GO:0022857)  NA  1    Q9Y2H0  Disks large-associated protein 4  transmembrane receptor regulatory/adaptor\nprotein(PC00226)  NA  NA  1    Q9Y493  Zonadhesin  cell adhesion molecule(PC00069);extracellular\nmatrix glycoprotein(PC00102)  NA  extracellular matrix(GO:0031012);extracellular\nregion(GO:0005576)  1    Q9Y5T5  Ubiquitin carboxyl-terminal hydrolase 16  #N/D  #N/D  #N/D  1    Q9Y5Y6  Suppressor of tumorigenicity 14 protein  annexin(PC00060);calmodulin(PC00050);peptide\nhormone(PC00131);protease\ninhibitor(PC00061);receptor(PC00207);serine\nprotease(PC00179)  NA  NA  1    Q9Y6U3  Adseverin  non-motor actin binding protein(PC00085)  actin binding(GO:0005488);structural constituent\nof cytoskeleton(GO:0005515)  actin\ncytoskeleton(GO:0043226);intracellular(GO:0005856)  1"
        },
        {
            "title": "No Title",
            "content": "PCOS Group  OD Group      Canonical Pathways  p-value  Overlap  p -value  Overlap    LXR/RXR Activation  9,04E -11  7.0%  9/128          FXR/RXR Activation  1,67E -10  6.6%  9/137          Extrinsic Prothrombin Activation Pathway  1,70E -07  22.2%  4/18          Acute Phase Response Signaling  5,21E -07  4.1%  7/171  3,06E -03  2.9%  5/171    Intrinsic Prothrombin Activation Pathway  1,48E -06  13.3%  4/30          Allograft Rejection Signaling        1,29E -02  3.5%  3/85    Communication between Innate and Adaptive Immune\nCells        1,50E -02  3.3%  3/90    Crosstalk between Dendritic Cells and Natural\nKiller Cells        1,50E -02  3.3%  3/90    Germ Cell-Sertoli Cell Junction Signaling        1,86E -02  2.3%  4/176"
        }
    ],
    "images": [
        {
            "caption": "Chart indicating the percentages of exclusive and upregulated FF proteins\nfrom the PCOS (dark grey) and OD (light grey) groups classified\naccording to protein classes based on the Gene Ontology database"
        },
        {
            "caption": "Chart indicating the percentages of exclusive and upregulated FF proteins\nfrom the PCOS and OD groups, classified according to cellular components\nbased on the Gene Ontology database"
        },
        {
            "caption": "Chart indicating the percentages of exclusive and upregulated FF proteins\nfrom the PCOS (dark grey) and OD (light grey) groups classified\naccording to biological processes based on the Gene Ontology\ndatabase"
        }
    ]
}